Have you ever been part of a Parkinson’s research study? This Parkinson’s Awareness Month, PDF says thank you for helping to bring about better treatments at a faster pace. After all, the only way that new treatments and a cure for Parkinson’s can be found is by ordinary people taking the extraordinary step of volunteering in studies.
Articles by this Author:
Dr. Francis Collins, Director of the National Institutes of Health (NIH), introduced him as the “Scientist in Chief.” And he introduced himself as “the kid who had trouble with high-school physics.” But there was no mistaking the passion for his subject of the man who stood in front of us in the East Room of the White House this morning, announcing a major federal initiative in brain science. It was President Obama at his rhetorical best, mixing easy banter with a deeply serious expression of his commitment to the brain research initiative that he described as the “next great American… Read More
Two Saturdays ago, in a Washington DC hotel, PDF pulled off an interesting little coup in its long-term bid to bring people with Parkinson’s (and other neurological disorders) into the center of conversations about the process of clinical research and drug development. The occasion was the plenary session on the last day of the annual scientific conference of the American Society for Experimental Neurotherapeutics (ASENT), and the title of the session was: New Models for Collaboration: Patients as Drivers and Partners in Neurological Research. I have served on the Board of Directors of this very worthwhile organization for three years… Read More
This week, a report conducted by IHS-Global was published in the journal Movement Disorders, providing the most comprehensive, economic analysis to date of the direct and indirect costs of Parkinson’s disease to individuals and society in the United States. (In full disclosure, it was underwritten by the Pharmaceutical Research and Manufacturers of America). While certain premises within the report – most notably, the estimate of the overall prevalence of Parkinson’s in the United States, which is probably on the low side – may be uncertain, most of the numbers are well thought through and carefully applied to the known data…. Read More
What makes PDF distinctive? As you may remember from September’s post, I am now answering such questions in my introductory letter for the Parkinson’s Disease Foundation’s quarterly newsletters, and posting them on the PDF blog, so we can begin a conversation with you. In PDF’s recently published Winter 2013 issue, I discussed what makes us distinctive, what we call The PDF Way. How does it play out in our programs? The PDF Way In our research portfolio, The PDF Way means supporting the creative ideas brought to us by scientific teams and individuals — peer-reviewed and time-tested. We provide long-term support to… Read More
Last month, the Parkinson’s community lost a dear member, one who dedicated his career to the treatment of the disease. William J. “Bill” Weiner, M.D., known to many at the University of Maryland where he served as Chairman of Neurology and the Director of the Maryland Parkinson’s Disease and Movement Disorders Center, passed away on December 29, 2012. Involved in treatment trials for Parkinson’s disease since levodopa in the 1960s, Bill was truly one of a kind in his profession – a fine scientist and a dedicated clinician who was committed to thinking for himself and to expressing his views… Read More